Clinical Trials Logo

Filter by:
NCT ID: NCT05996458 Recruiting - Digestive Disease Clinical Trials

A Population-based, Multicenter Cohort Study of Combined Screening for Gastrointestinal Tumors

Start date: August 1, 2023
Phase:
Study type: Observational

To establish combined gastroenteroscopy screening and follow-up management for gastrointestinal tumors, explore and evaluate the feasibility and health economic benefits of combined screening for esophagus, stomach and colorectal cancer

NCT ID: NCT05996380 Recruiting - T2DM Clinical Trials

A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes

Start date: June 9, 2023
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, single-dose escalation trial was designed. There are 6 dose groups and 1 optional dose group: 0.5 mg, 2 mg, 8 mg, 25mg, 50 mg, 100 mg and 150 mg (optional). Eight healthy adult subjects or T2DM patients in each dose group (except for 0.5 mg dose group, only 4 subjects will be enrolled) are randomly assigned to subcutaneously injection of SHR-3167 or placebo according to 3:1 ratio.

NCT ID: NCT05996016 Recruiting - HIV Infections Clinical Trials

Gut and Vaginal Microbiota Profile Study for HIV Women

Start date: November 9, 2022
Phase:
Study type: Observational [Patient Registry]

Women Living with HIV Infection (WLHIV)are intended to acquire HPV infection which usually contributes to variable cervical lesions. we hypothesize that vaginal microbiota imbalance may make WLHIV prone to HPV infection,thereafter results in severe cervical lesion.

NCT ID: NCT05995847 Recruiting - COPD Clinical Trials

Effectiveness of Harmonica Playing in Improving Lung Function Among COPD Patients

Start date: December 5, 2023
Phase: N/A
Study type: Interventional

Although it has been documented that harmonica playing plays a role in the pulmonary rehabilitation (PR) of patients with chronic obstructive pulmonary disease (COPD), current studies are limited by small sample sizes, uncomprehensive outcome indicators, and short intervention durations. Thus, the investigators aim to compare the harmonica combination group with the basic-PR-care group in terms of improving health outcomes among COPD patients, such as lung function, self-efficacy, quality of life, compliance with training, and emotional distress.

NCT ID: NCT05995327 Recruiting - Spine Deformity Clinical Trials

Reasons and Risk Factors for Unplanned Spinal Re-operation

Start date: January 1, 2012
Phase:
Study type: Observational

Unplanned re-operation is one of the common negative indicators reflecting the quality and safety of surgery in the medical industry and has become one of the ten goals for the improvement of national medical quality and safety in China since 2022, while about 40% of unplanned re-operations in Peking University Third Hospital in recent years occur in spine patients of the orthopedics department. This project intends to establish a high-quality and sustainable ambispective disease cohort for spine surgery in Peking University Third Hospital based on the unplanned re-operations that occurred in the Orthopedics Department of Peking University Third Hospital from January 2012 to December 2025. The investigators further summarize and analyze clinical causes and risk factors of re-operations, aiming to explore scientific coping strategies and provide reference for continuous improvement of medical service quality.

NCT ID: NCT05995093 Recruiting - Clinical trials for Disseminated Intravascular Coagulation

The Proactive Diagnostic Value of Hemostatic Biomarkers in Disseminated Intravascular Coagulation

Start date: December 1, 2022
Phase:
Study type: Observational

The project was undertaking by Qilu Hospital of Shandong University, aiming to evaluate diagnostic performance of hemostatic biomarkers in disseminated intravascular coagulation.

NCT ID: NCT05995054 Recruiting - Clinical trials for Immune Thrombocytopenia

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia

2023CD20ITP
Start date: August 28, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of Obinutuzumab in the treatment of immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment.

NCT ID: NCT05995041 Recruiting - Clinical trials for Acute Myeloid Leukemia

Universal CAR-T Cells Targeting AML

Start date: October 31, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T-cell products targeting CLL-1, CD33, CD38 and CD123 in patients with relapsed and refractory AML. The study also aims to learn more about the function of the universal CAR T cells and their persistency in AML patients.

NCT ID: NCT05995028 Recruiting - Clinical trials for Acute Myeloid Leukemia

Universal 4SCAR7U Targeting CD7-positive Malignancies

Start date: October 31, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hematological malignancies using CD7 specific universal CAR T cells. The study also aims to learn more about the function of CD7 targeting CAR T cells and their persistence in patients of hematological malignancies.

NCT ID: NCT05995015 Recruiting - B Cell Malignancies Clinical Trials

4SCAR19U T Cells Targeting B Cell Malignancies

Start date: October 31, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the feasibility, safety and efficacy of universal CAR T cell therapy against CD19-positive hematological malignancies using a novel CD19-specific CAR T cell product, 4SCAR19U T cells. The study also aims to learn more about the function of the 4SCAR19U T cells and their persistence in patients. This is a phase I trial enrolling patients from multiple clinical centers.